###begin article-title 0
###xml 13 20 13 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
Mutations in PIK3CA are infrequent in neuroblastoma
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 268 272 268 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 320 324 320 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 334 338 334 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Braf</italic>
###xml 449 453 449 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 462 469 462 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 543 550 543 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 649 654 649 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 743 747 743 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 758 763 758 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Braf </italic>
###xml 506 511 <span type="species:ncbi:9606">human</span>
###xml 566 571 <span type="species:ncbi:9606">human</span>
###xml 628 643 <span type="species:ncbi:10090">transgenic mice</span>
###xml 701 707 <span type="species:ncbi:10090">murine</span>
Neuroblastoma is a frequently lethal pediatric cancer in which MYCN genomic amplification is highly correlated with aggressive disease. Deregulated MYC genes require co-operative lesions to foster tumourigenesis and both direct and indirect evidence support activated Ras signaling for this purpose in many cancers. Yet Ras genes and Braf, while often activated in cancer cells, are infrequent targets for activation in neuroblastoma. Recently, the Ras effector PIK3CA was shown to be activated in diverse human cancers. We therefore assessed PIK3CA for mutation in human neuroblastomas, as well as in neuroblastomas arising in transgenic mice with MYCN overexpressed in neural-crest tissues. In this murine model we additionally surveyed for Ras family and Braf mutations as these have not been previously reported.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 89 96 89 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 332 336 332 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hras1</italic>
###xml 359 365 359 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kras2 </italic>
###xml 369 373 369 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nras</italic>
###xml 404 411 404 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pik3ca </italic>
###xml 415 419 415 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Braf</italic>
###xml 11 16 <span type="species:ncbi:9606">human</span>
###xml 499 514 <span type="species:ncbi:10090">transgenic mice</span>
Sixty-nine human neuroblastomas (42 primary tumors and 27 cell lines) were sequenced for PIK3CA activating mutations within the C2, helical and kinase domain "hot spots" where 80% of mutations cluster. Constitutional DNA was sequenced in cases with confirmed alterations to assess for germline or somatic acquisition. Additionally, Ras family members (Hras1, Kras2 and Nras) and the downstream effectors Pik3ca and Braf, were sequenced from twenty-five neuroblastomas arising in neuroblastoma-prone transgenic mice.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 31 38 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 217 222 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 256 263 256 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 276 281 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 445 449 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 486 491 486 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hras1</italic>
###xml 493 498 493 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kras2</italic>
###xml 500 504 500 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nras</italic>
###xml 506 512 506 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pik3ca</italic>
###xml 517 522 517 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Braf </italic>
###xml 579 584 579 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN-</italic>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 605 610 <span type="species:ncbi:10090">mouse</span>
We identified mutations in the PIK3CA gene in 2 of 69 human neuroblastomas (2.9%). Neither mutation (R524M and E982D) has been studied to date for effects on lipid kinase activity. Though both occurred in tumors with MYCN amplification the overall rate of PIK3CA mutations in MYCN amplified and single-copy tumors did not differ appreciably (2 of 31 versus 0 of 38, respectively). Further, no activating mutations were identified in a survey of Ras signal transduction genes (including Hras1, Kras2, Nras, Pik3ca, or Braf genes) in twenty-five neuroblastic tumors arising in the MYCN-initiated transgenic mouse model.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 253 257 253 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 350 355 350 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 378 383 <span type="species:ncbi:9606">human</span>
###xml 394 400 <span type="species:ncbi:10090">murine</span>
These data suggest that activating mutations in the Ras/Raf-MAPK/PI3K signaling cascades occur infrequently in neuroblastoma. Further, despite compelling evidence for MYC and RAS cooperation in vitro and in vivo to promote tumourigenesis, activation of RAS signal transduction does not constitute a preferred secondary pathway in neuroblastomas with MYCN deregulation in either human tumors or murine models.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 844 847 844 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras</italic>
###xml 849 853 849 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 855 861 855 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A</italic>
###xml 863 866 863 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1</italic>
###xml 949 954 949 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1114 1115 1114 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1116 1117 1116 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 823 828 <span type="species:ncbi:9606">human</span>
Neuroblastoma is a common childhood tumor arising from neural crest-derived cells of the sympathetic nervous system. It is one of the most extensively characterized solid tumors at the genomic level and provides the paradigm for the clinical utility of genomic alterations in defining tumor phenotype. Much of the clinical heterogeneity seen with this tumor (spanning spontaneous regression to relentless disease progression) can be attributed to distinct tumor-specific genetic alterations that correlate strongly with disease course. These include genomic loss within 1 p and 11 q, and gain of 17 q, among others. Still, little is known about the genes or cellular processes targeted by the majority of these genomic changes. Key regulatory genes frequently targeted for activation or inactivation in a plethora of adult human cancers (e.g., Ras, TP53, CDKN2A, RB1) are rarely, if ever, mutated in neuroblastoma. The sole exception to this is the MYCN proto-oncogene, which is markedly amplified and overexpressed in ~22% of neuroblastomas and independently correlates with advanced disease and adverse outcome [1,2].
###end p 11
###begin p 12
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 296 300 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 360 363 360 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 625 629 625 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 655 659 655 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 718 719 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 732 736 732 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 757 761 757 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 833 834 833 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 978 979 978 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 980 981 980 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1134 1139 1134 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1154 1159 1154 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 703 708 <span type="species:ncbi:9606">human</span>
###xml 1075 1080 <span type="species:ncbi:9606">human</span>
Deregulated expression of MYC genes, including MYCN, inhibits cellular differentiation and promotes mitogen-independent proliferation [3]. However, sensitivity to apoptotic stressors is concurrently enhanced as a safeguard against neoplastic transformation, and therefore oncogenesis mediated by MYC genes requires co-operating lesions that either disable the MYC-death signaling axis [4,5] or repress it through constitutive survival signals. We are interested in defining these co-operating lesions, in addition to identifying oncogenic lesions that contribute to neuroblastoma tumourigenesis or progression independent of MYCN. Activating mutations in Ras family genes have been identified in 30% of human cancers [6]. Activated Ras (1) co-operates with MYC to transform primary cells in vitro and promote tumourigenesis in vivo [7]; (2) regulates myriad cellular processes including survival; and (3) acts to stabilize Myc proteins through post-translational modifications [8,9]. These data strongly support this pivotal pathway as a candidate for aberrant activation in human neuroblastoma, and specifically in co-operating with MYCN in tumors with MYCN amplification or deregulated expression.
###end p 12
###begin p 13
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HRAS1</italic>
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NRAS </italic>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 247 251 247 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF1 </italic>
###xml 290 302 290 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SHP2/PTPN11 </italic>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 786 791 786 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRAF </italic>
###xml 795 802 795 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 975 977 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 995 999 995 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 1090 1092 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1178 1185 1178 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 1435 1442 1435 1442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 1482 1486 1482 1486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 1589 1596 1589 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 83 88 <span type="species:ncbi:9606">human</span>
###xml 567 572 <span type="species:ncbi:9606">human</span>
###xml 729 734 <span type="species:ncbi:9606">human</span>
###xml 1309 1314 <span type="species:ncbi:9606">human</span>
Still, activating mutations have rarely been identified in HRAS1, KRAS2 or NRAS in human neuroblastoma [10-12]. Occasional Ras effector alterations have been identified but collectively they are infrequent. These include biallelic inactivation of NF1 and mutations in the Noonan-associated SHP2/PTPN11 gene [13-16]. Downstream of Ras are multiple signal transduction pathways responsible for the execution of Ras-mediated cellular effects [17] and cell-type and species specificity for transformation has been noted [18]. The most widely validated as contributing to human tumorigenesis include the Raf-MAPK and phosphatidylinositol 3-kinase (PI3K) pathways [19,20]. Somatic activating mutations have been identified in multiple human cancers within these pathways, particularly in the BRAF and PIK3CA genes, respectively [21,22]. Activated PI3K signaling has been proposed to foster Myc/Ras co-operativity through Akt-mediated phosphorylation of FoxO transcription factors [23] to de-represses MYC target genes, and activated PI3K genes protect against Myc induced cell death sensitivity [24]. These Ras effector signaling components have not been studied in neuroblastoma. As PIK3CA has been shown to be activated through somatic mutation in >25% of colorectal, breast and ovarian carcinomas, as well as in human CNS tumors (including anaplastic oligodendrogliomas, glioblastoma multiforme and medulloblastoma), we hypothesized that PIK3CA mutations may substitute for activating RAS lesions in neuroblastoma tumourigenesis. Therefore, we performed a targeted sequencing analysis of the PIK3CA gene in primary neuroblastomas and neuroblastoma-derived cell lines.
###end p 13
###begin p 14
###xml 176 181 176 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 623 628 623 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 771 776 771 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 803 808 803 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hras1</italic>
###xml 810 815 810 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kras2</italic>
###xml 817 821 817 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nras</italic>
###xml 823 828 823 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Braf </italic>
###xml 832 839 832 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pik3ca </italic>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
###xml 150 153 <span type="species:ncbi:10090">GEM</span>
###xml 170 175 <span type="species:ncbi:9606">human</span>
###xml 247 250 <span type="species:ncbi:10116">rat</span>
###xml 516 521 <span type="species:ncbi:9606">human</span>
###xml 590 595 <span type="species:ncbi:9606">human</span>
To further explore Raf-MAPK and PI3K signaling in neuroblastic tumors we evaluated tumors arising in neuroblastoma-prone genetically engineered mice (GEM). In this model human MYCN gene overexpression is targeted to neural crest tissues using the rat tyrosine hydroxylase promoter [25]. Neuroblastic tumors arise stochastically within the sympathetic ganglia with near-complete penetrance. These tumors are genomically complex with chromosomal gains and losses at regions orthologous to regions similarly altered in human neuroblastoma [26,27]. Thus, the model faithfully recapitulates the human condition with deregulated MYCN as the initiating event biologically and genetically [25-27]. To determine whether alterations in Ras/Raf/PIK signaling were co-operating with MYCN in this model we sequenced Hras1, Kras2, Nras, Braf and Pik3ca to assess for activating mutations as these genes and pathways have not been studied previously using this model.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human neuroblastoma specimens
###end title 16
###begin p 17
###xml 131 138 131 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 286 293 286 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 743 750 743 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 82 90 <span type="species:ncbi:9606">Children</span>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
###xml 464 472 <span type="species:ncbi:9606">Children</span>
###xml 587 595 <span type="species:ncbi:9606">Children</span>
Forty-two (42) primary neuroblastoma-derived DNA specimens were acquired from the Children's Oncology Group (COG; Arcadia, CA) for PIK3CA sequence analysis. Constitutional DNA samples were subsequently obtained from the COG Nucleic Acids bank for two patients with tumors demonstrating PIK3CA sequence alterations to determine whether these were tumor-specific (somatic) or germ line in origin. These studies were approved by the Institutional Review Board at The Children's Hospital of Philadelphia. Twenty-seven (27) additional neuroblastoma cell line DNA specimens, obtained from The Children's Hospital of Philadelphia cell line bank and the Wellcome Trust Sanger Institute and reported previously [28,29], were similarly investigated for PIK3CA mutations.
###end p 17
###begin title 18
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine neuroblastoma specimens
###end title 18
###begin p 19
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 167 175 167 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TH-MYCN </italic>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 386 391 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 436 444 436 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TH-MYCN </italic>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
###xml 87 92 <span type="species:ncbi:9606">human</span>
###xml 132 135 <span type="species:ncbi:10116">rat</span>
###xml 175 178 <span type="species:ncbi:10090">GEM</span>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
###xml 444 447 <span type="species:ncbi:10090">GEM</span>
###xml 462 470 <span type="species:ncbi:9606">Children</span>
###xml 955 960 <span type="species:ncbi:10090">mouse</span>
###xml 1053 1061 <span type="species:ncbi:9606">Children</span>
Twenty-five (25) tumors were harvested from genetically engineered mice overexpressing human MYCN in neural-crest tissues under the rat tyrosine-hydroxylase promoter [TH-MYCN GEM model] [25]. In this model, tumors arise stochastically within the peripheral sympathetic nervous system (in the retroperitoneum or posterior thorax) with near-complete penetrance in mice homozygous for the MYCN transgene. Founders for establishment of the TH-MYCN GEM colony at The Children's Hospital of Philadelphia were generously provided by Dr. William Weiss (UCSF). Ten tumors in this study came from early backcrosses (received from UCSF) and fifteen additional tumors came from animals backcrossed to homozygosity in the 129X1/SvJ background. Tumors were flash frozen at necropsy and partitioned for subsequent DNA and RNA extraction using the DNeasy and RNeasy Midi Tissue kits, respectively, according to the manufacturer's instructions (Qiagen; Valencia, CA). All mouse experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at The Children's Hospital of Philadelphia.
###end p 19
###begin title 20
###xml 27 39 27 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">human PIK3CA</italic>
###xml 27 32 <span type="species:ncbi:9606">human</span>
Candidate gene sequencing: human PIK3CA
###end title 20
###begin p 21
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 69 74 <span type="species:ncbi:9606">human</span>
###xml 274 279 <span type="species:ncbi:9606">human</span>
Primer pairs that amplify exons 4, 5, 9 and 20 of the PIK3CA gene in human tumors were synthesized (Integrated DNA Technologies, Inc., Coralville, 1A). These exons encode the C2, helical, and kinase domains, respectively, which demonstrate high rates of somatic mutation in human cancers [22]. The four primer pairs used to amplify exons 5, 9 and 20 from genomic DNA were identical to those used by Samuels, et al. [22]. Primers that amplify exon 4 were designed using Primer 3 software : HumPIK3CA-ex4-F1, 5'-TCT TGT GCT TCA ACG TAA ATC C-3', and HumPIK3CA-ex4-R1, 5'-CGG AGA TTT GGA TGT TCT CC-3'. PCR amplification with each pair yielded a single specific band of appropriate size using control genomic DNA input.
###end p 21
###begin title 22
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine Pik3ca
###end title 22
###begin p 23
###xml 126 133 126 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pik3ca </italic>
Primer pairs that amplify exons 9 and 20 (helical and kinase domains, respectively) were designed using Primer 3 software and Pik3ca sequence (accession no. GenBank:). These were: (1) MurPIK3CA-ex9-F1, 5'-CCA AGG AAA TCA TGG CAG AG-3', and MurPIK3CA-ex9-R1, 5'-TGT CCC TGA CAG GAA GAA GG-3'; and (2) MurPIK3CA-ex20-F1, 5'-GCA GCT CAC TGA CCA GAT GT-3', and MurPIK3CA-ex20-R1, 5'-ACT GCC ATG CAG TGG AGA A-3'. Amplification of genomic DNA (control) yielded appropriate single products of 240 and 358 base pairs, respectively.
###end p 23
###begin title 24
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine Ras/Raf pathway genes
###end title 24
###begin p 25
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hras1 </italic>
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kras2 </italic>
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nras </italic>
###xml 603 608 603 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Braf </italic>
###xml 56 62 <span type="species:ncbi:10090">murine</span>
Primer sequences to amplify the entire coding region of murine Hras1 (GenBank:), Kras2 (GenBank:), and Nras (GenBank:) from cDNA were kindly provided by Lewis Chodosh (University of Pennsylvania). These are: (1) mHRAS1-F1-seq, 5'-AGA ATA CAA GCT TGT GGT GGT GG-3', and mHRAS1-R1-seq, 5'-CCT GTA CTG ATG GAT GTC CTC G-3'; (2) mKRAS2-F1-seq, 5'-GTA AGG CCT GCT GAA AAT G-3', and mKRAS2-R1-seq, 5'-GGT GAA TAT CTT CAA ATG AT-3'; and (3) mNRAS-F1-seq, 5'-GGT CTC CAA CAG CTC AGG TTG AAG-3', and mNRAS-R1-seq, 5'-GTA CCT GTA GAG GTT AAT ATC TGC A-3'. Primers to amplify the serine/threonine kinase domain of Braf () were designed using Primer 3 software, and were: mBRAF-F2, 5'-GAA TGT GAC AGC ACC CAC AC-3', and mBRAF-R1, 5'-CGG GTT TTT ATC TTG CAT TC-3'. All primer pairs amplified a single reaction product of predicted size from control cDNA.
###end p 25
###begin title 26
PCR amplification, sequencing and mutation detection
###end title 26
###begin p 27
###xml 193 194 191 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 284 285 281 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Two PCR reactions were carried out for each sequencing reaction in a final volume of 20 mul. The reaction mixture consisted of 5 mul stock Master Mix (16 ml TaqGold Buffer II, 9.6 ml 25 mM MgCl2, 5.2 ml 2% Ficoll, 200 mul 0.025% Bromophenol Blue, 1.6 ml 10 nM dNTP Mix, and 7.4 ml ddH2O), 0.4 mul 20 muM Forward-primer, 0.4 mul 20 muM Reverse-primer, 13.0 mul sterile PCR-grade water, 0.2 mul TaqGold DNA Polymerase (Promega Corporation, Madison, Wl), and 1.0 mul sample template. For sequencing from DNA, 80 ng were used as template input. For sequencing from cDNA, 2 mug RNA was reverse-transcribed in a final volume of 20 mul with the oligodeoxythymidylic acid primer using the Superscript II pre-amplification system according to the manufacturer's instructions (Life Technologies, Gaithersburg, MD). One mul of reverse transcribed cDNA was used as a template. The following PCR protocol was utilized for each sample and carried out in a Programmable Thermal Controller-100 (MJ Research, Inc., Waltham, MA): (1) 94degreesC x 12 minutes (polymerase activation), (2) thirty DNA polymerization cycles of 94degreesC x 45 seconds, 55degreesC x 45 seconds, 72degreesC x 45 seconds, followed by 72degreesC x 10 minutes and 4degreesC holding temperature. The individual PCR amplifications for each reaction were combined and electrophoresed through a 1% agarose gel in 1x TBE buffer for 40 minutes at 90 V. The PCR product was verified as a single specific band of predicted size then extracted and purified using the QIAQuick Gel Extraction Kit (Qiagen Inc., Valencia, CA).
###end p 27
###begin p 28
All amplification products were sequenced bi-directionally in an automatic sequencer (Applied Biosystems, Foster, CA) using the primary forward and reverse primers. This provided at least double coverage of all evaluated sequence in each tumor sample. Sequence analysis was carried out using Sequencher version 4.1.4 (Gene Codes Corporation, Ann Arbor, MI) in addition to a manual chromatogram review. Confirmatory resequencing from replicate PCR amplification reactions was performed for any sequence that was ambiguous or deviated from wild-type so that all abnormal sequences were confirmed in at least quadruplicate from replicate amplification reactions.
###end p 28
###begin title 29
Results and discussion
###end title 29
###begin title 30
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 29 34 <span type="species:ncbi:9606">human</span>
PIK3CA mutation screening in human neuroblastoma
###end title 30
###begin p 31
###xml 100 107 100 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 168 175 168 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 495 502 495 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 531 533 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 874 876 874 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 941 942 941 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 224 229 <span type="species:ncbi:9606">human</span>
We screened 69 human neuroblastomas (42 primary tumors and 27 neuroblastoma-derived cell lines) for PIK3CA gene mutations within exons 4, 5, 9 and 20 (Tables 1 and 2). PIK3CA is one of the most commonly mutated oncogenes in human cancers, occurring at high prevalence in tumors of the colon, breast, ovary, stomach and liver, and at lower prevalence in multiple other cancer types. Exons 9 and 20 encode portions of the helical and kinase domains, respectively, that ~80% of previously reported PIK3CA mutations cluster within [22,30]. These regions encode critical domains mediating lipid kinase activity [31]. Exons 4 and 5 encode the C2 region of the protein (calcium-dependent phospholipid binding domain) that is mutated in an additional ~5% of tumors, yet this region accounts for 50% of mutations reported in glioblastoma multiforme, a highly malignant neural tumor [22], so we included it in our neuroblastoma investigations (Figure 1).
###end p 31
###begin p 32
###xml 9 16 9 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1039 1041 1039 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1189 1194 1189 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1504 1506 1504 1506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 758 765 <span type="species:ncbi:9606">patient</span>
Overall, PIK3CA mutations were infrequently found, with non-synonymous coding sequence alterations being identified in 2 of 69 specimens (2.9%). An additional 16 tumors had sequence alterations identified in non-coding regions (including three specific alterations in introns and one in the 3'-untranslated region). Of the coding sequence mutations, one was identified within the helical domain encoded within exon 9, occurring in the MYCN amplified neuroblastoma cell line NLF. This heterozygous missense mutation (G to T) results in an arginine to methionine substitution (R524M). This mutation has not to our knowledge been reported previously and is of undetermined functional significance. No constitutional nor primary tumor DNA was available from the patient the cell line was derived from so it could not be directly confirmed that this was a somatic mutation, nor whether the mutation occurred in vivo or ex vivo during the course of tissue culture propagation. The second mutation was identified within the kinase domain (Figure 2A). This was a heterozygous G to T alteration leading to a glutamic acid to aspartic acid substitution (E982D) in primary tumor #1070 (INSS stage 3, MYCN amplified). Constitutional DNA from this individual was wild-type, confirming the kinase domain mutation to be tumor-specific (somatic). This specific mutation has not been previously described nor functionally characterized to date, although an E982K mutation has been found in anaplastic thryroid carcinoma [32].
###end p 32
###begin p 33
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 519 526 <span type="species:ncbi:9606">patient</span>
In addition, four unique sequence alterations were identified in at least one specimen each in non-coding regions: two within intron 8 (C19339T and G19361A [nucleotide number refers to position in genomic sequence relative to the first nucleotide of exon 1]), one within intron 9 (T19623G), and one within the 3'-UTR (heterozygous T35577C). These were identified in 5 (7.2%), 1 (1.4%), 9 (13%) and 1 (1.4%) sample, respectively. The 3'-UTR alteration was identified in primary tumor #1218. Constitutional DNA from this patient was sequenced and demonstrated the same alteration, suggesting this represents a polymorphic variant (Figure 2B). None of these alterations appears to disrupt splice donor or acceptor sites. However, none of these alterations represents a previously identified SNP based on a query of the dbSNP (build 125; ). Finally, no mutations were identified within exons 4 or 5 within the C2 domain in any neuroblastoma tissue.
###end p 33
###begin p 34
###xml 6 12 6 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA</italic>
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 208 213 208 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 247 252 247 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 865 867 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 893 895 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1000 1007 1000 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 116 121 <span type="species:ncbi:9606">human</span>
Thus, PIK3CA, like RAS genes, is an infrequent target for activating mutation in neuroblastoma. In our series of 69 human neuroblastomas, amino acid sequence alterations were identified in only two (one in a MYCN amplified cell line, and one in a MYCN amplified INSS stage 3 tumor), albeit in a survey restricted to domain "hotspots" (C2, helical, kinase) that harbor >80% of mutations identified to date [22]. Although these alterations occur within regions where mutations cluster, it is not known whether they augment lipid kinase activity and are functionally significant. Still, we did not identify any synonymous sequence alterations in the coding regions assessed so random non-selected alterations are infrequent. Of note, these findings are consistent with similar low frequencies of mutation (<5%) in other embryonal malignancies such as medulloblastoma [33] and leukemia/lymphomas [30], in contrast to the higher prevalence of mutations in many adult epithelial cancers. The prevalence of PIK3CA mutations in other pediatric cancers has not yet been reported.
###end p 34
###begin title 35
###xml 18 21 18 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras</italic>
###xml 23 26 23 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Raf</italic>
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI3K </italic>
###xml 44 50 <span type="species:ncbi:10090">murine</span>
###xml 112 117 <span type="species:ncbi:10090">mouse</span>
###xml 119 122 <span type="species:ncbi:10090">GEM</span>
Assessment of the Ras, Raf, PI3K pathway in murine neuroblastomas arising in the TH-MYCN genetically engineered mouse (GEM)
###end title 35
###begin p 36
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 295 298 295 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras</italic>
###xml 300 304 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Raf </italic>
###xml 311 316 311 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pi3k </italic>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 430 437 430 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pi3kca </italic>
###xml 645 652 645 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pik3ca </italic>
###xml 668 669 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 62 65 <span type="species:ncbi:10090">GEM</span>
###xml 211 216 <span type="species:ncbi:9606">human</span>
###xml 591 595 <span type="species:ncbi:10090">mice</span>
###xml 604 610 <span type="species:ncbi:10090">murine</span>
Neuroblastomas arise with near-complete penetrance in TH-MYCN GEM homozygous for the transgene. Tumors develop focally in the peripheral nervous system and demonstrate genomic complexity with high similarity to human neuroblastomas [26]. For this reason, we used this model to determine whether Ras, Raf and/or Pi3k signaling constituted a preferred secondary pathway with MYCN deregulation. To assess for activating mutations in Pi3kca we sequenced the helical and kinase encoding regions (exons 9 and 20) from 25 neuroblastomas harvested from heterozygous or homozygous transgene carrying mice. All 25 murine neuroblastomas harbored wild-type Pik3ca sequence (Table 3).
###end p 36
###begin p 37
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Raf </italic>
###xml 100 105 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hras1</italic>
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kras2</italic>
###xml 114 119 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nras </italic>
###xml 123 127 123 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Braf</italic>
###xml 182 185 182 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 376 381 376 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hras1</italic>
###xml 383 389 383 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kras2 </italic>
###xml 393 398 393 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nras </italic>
###xml 474 480 474 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kras2 </italic>
###xml 487 488 487 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 786 792 786 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pik3ca</italic>
###xml 794 798 794 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 810 815 810 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Braf </italic>
###xml 1011 1016 1011 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 67 73 <span type="species:ncbi:10090">murine</span>
###xml 161 166 <span type="species:ncbi:9606">human</span>
###xml 196 202 <span type="species:ncbi:10090">murine</span>
###xml 585 589 <span type="species:ncbi:10090">mice</span>
###xml 869 872 <span type="species:ncbi:10090">GEM</span>
###xml 1051 1054 <span type="species:ncbi:10090">GEM</span>
###xml 1084 1089 <span type="species:ncbi:9606">human</span>
We next assessed genes in the Ras and Raf pathway in these same 25 murine neuroblastomas, including Hras1, Kras2, Nras and Braf, which are frequently mutated in human cancers and in MYC-initiated murine tumor models [34]. No non-synonymous sequence alterations were identified in these genes. One tumor (THMYCN-21) had three synonymous alterations identified: one each in the Hras1, Kras2 and Nras genes. One additional synonymous alterations was identified in THMYCN-17 in Kras2 (Table 3). These findings likely represent polymorphic variants and were found only in tumors from early mice backcrosses predicted to harbor strain specific polymorphisms. Tumors harvested following extensive backcrossing to homozygosity had no non-synonymous alterations identified. The low frequency of Pik3ca, Ras family, and Braf activating mutations in tumors arising in the TH-MYCN GEM supports that activated Ras-mediated signal transduction is not a pre-requisite for neuroblastoma development in concert with deregulated MYCN in this model. In this respect the GEM model is consistent with the human tumor.
###end p 37
###begin title 38
Conclusion
###end title 38
###begin p 39
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pik3ca</italic>
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Braf </italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 326 330 326 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 376 380 376 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Myc </italic>
###xml 394 398 394 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 561 566 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 679 684 679 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 896 900 896 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 986 988 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 66 71 <span type="species:ncbi:9606">human</span>
###xml 95 101 <span type="species:ncbi:10090">murine</span>
Pik3ca, Ras family, and Braf activating mutations occur rarely in human neuroblastomas or in a murine model driven by neural-restricted MYCN overexpression. These data support that activated Ras-mediated signal transduction does not constitute a preferred secondary pathway for neuroblastic tumors in concert with deregulated MYCN. This despite the potent cooperation between Myc and activated Ras genes demonstrable in vitro and in vivo to induce transformation and/or tumorigenicity. Further, these tumor promoting pathways are rarely targeted independent of MYCN deregulation as demonstrated by the absence of activating lesions in neuroblastoma tumors and cell lines without MYCN amplification. Tumor induction through activation of Ras/Raf-MAPK/PI3K pathways clearly demonstrates cell-type specificity. For example, studies have demonstrated epithelial cell proliferation being augmented by Ras activation while mesenchymal cells (e.g., fibroblasts) demonstrate growth inhibition [35]. This specificity may underscore the variable frequency of Ras pathway mutation selection across cancers and partly explain the paucity of activating mutations found in non-epithelial embryonal malignancies such as neuroblastoma.
###end p 39
###begin p 40
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 166 171 166 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRAS </italic>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 180 185 180 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RRAS </italic>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 516 523 516 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 611 613 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 825 832 825 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1094 1096 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1100 1108 1100 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 1210 1212 1210 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1406 1410 1406 1410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
However, it remains strictly possible that activating mutations in alternative Ras signaling constituents occur in neuroblastoma. Less studied family members such as MRAS [36] and RRAS [37] have oncogenic potential in mammalian cells and the former demonstrates restricted expression to neural tissues. These have not been investigated in neuroblastoma although both are expressed in primary neuroblastomas at the mRNA level (data not shown). In distinction to activating point mutations, pathway activation through PIK3CA gene dosage effects following low level genomic amplification have also been described [38]. However, these appear predominantly in those epithelial carcinomas (breast, ovarian, gastric carcinoma) in which activating mutations occur at higher frequency as well. In contrast, gain of 3q26 including the PIK3CA locus is infrequently reported in neuroblastoma cells, including in those cell lines studied herein [28]. Finally, additional effector arms to Ras-mediated signaling may play a role in tumourigenesis. These include Tiam-1, RalGDS, RASSF and others (reviewed in [17]). RASSF1A has been shown to be epigenetically silenced in a significant proportion of high-risk neuroblastomas [39] and elimination of this potentially pro-apoptotic pathway may be more critical than activation of proliferative or survival signaling in the establishment of embryonal cancers. Alternatively, Ras independent secondary pathways may be preferentially co-opted in neuroblastoma tumor initiation. These pathways remain elusive but certainly warrant further investigation, as defining the preferred pathways deregulated in neuroblastoma might provide suitable novel targets for directed therapies against this frequently lethal tumor.
###end p 40
###begin title 41
Abbreviations
###end title 41
###begin p 42
INSS: International Neuroblastoma Staging System; MAPK: mitogen-activated protein kinase.
###end p 42
###begin title 43
Competing interests
###end title 43
###begin p 44
The author(s) declare that they have no competing interests.
###end p 44
###begin title 45
Authors' contributions
###end title 45
###begin p 46
###xml 76 83 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 201 205 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Raf </italic>
###xml 91 96 <span type="species:ncbi:9606">human</span>
###xml 101 107 <span type="species:ncbi:10090">murine</span>
###xml 218 224 <span type="species:ncbi:10090">murine</span>
VD and BM carried out the molecular analysis and performed data analyses of PIK3CA in both human and murine tumors. PM carried out the molecular analysis and performed data analyses for Ras family and Raf genes in the murine model. MDH conceived of the study, directed its design, coordination and data analysis and edited the manuscript. All authors read and approved the final manuscript.
###end p 46
###begin title 47
Pre-publication history
###end title 47
###begin p 48
The pre-publication history for this paper can be accessed here:
###end p 48
###begin p 49

###end p 49
###begin title 50
Acknowledgements
###end title 50
###begin p 51
###xml 362 366 362 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 22 30 <span type="species:ncbi:9606">Children</span>
###xml 200 206 <span type="species:ncbi:10090">murine</span>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
###xml 274 282 <span type="species:ncbi:9606">Children</span>
###xml 477 485 <span type="species:ncbi:9606">Children</span>
###xml 715 723 <span type="species:ncbi:9606">Children</span>
The authors thank the Children's Oncology Group (COG) for the provision of primary neuroblastoma and constitutional DNA; William Weiss (University of California at San Francisco) for the provision of murine tumors and founder mice for establishing the TH-MYCN colony at The Children's Hospital of Philadelphia; and Lewis Chodosh (University of Pennsylvania) for Ras family sequencing primers. We also thank Eric Rappaport and the Nucleic Acids and Protein Core Facility at The Children's Hospital of Philadelphia for sequencing support; and Rosalind Barr and Kim Davis for animal colony maintenance. This work was supported by NIH CA97323 (MDH) and the Richard and Sheila Sanford Chair in Pediatric Oncology at The Children's Hospital of Philadelphia (MDH).
###end p 51
###begin article-title 52
###xml 36 41 <span type="species:ncbi:9606">human</span>
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
###end article-title 52
###begin article-title 53
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
###end article-title 53
###begin article-title 54
Deconstructing Myc
###end article-title 54
###begin article-title 55
Induction of apoptosis in fibroblasts by c-myc protein
###end article-title 55
###begin article-title 56
The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification
###end article-title 56
###begin article-title 57
###xml 17 22 <span type="species:ncbi:9606">human</span>
ras oncogenes in human cancer: a review
###end article-title 57
###begin article-title 58
Signaling networks that link cell proliferation and cell fate
###end article-title 58
###begin article-title 59
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
###end article-title 59
###begin article-title 60
###xml 50 55 <span type="species:ncbi:9606">human</span>
Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest
###end article-title 60
###begin article-title 61
Incidence of ras gene mutations in neuroblastoma
###end article-title 61
###begin article-title 62
###xml 29 34 <span type="species:ncbi:9606">human</span>
Activated N-ras oncogenes in human neuroblastoma
###end article-title 62
###begin article-title 63
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras </italic>
Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas and medullary thyroid cancers
###end article-title 63
###begin article-title 64
###xml 75 80 <span type="species:ncbi:9606">human</span>
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia
###end article-title 64
###begin article-title 65
###xml 32 37 <span type="species:ncbi:9606">human</span>
Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras
###end article-title 65
###begin article-title 66
###xml 70 77 <span type="species:ncbi:9606">patient</span>
Homozygous deletion of the neurofibromatosis-1 gene in the tumor of a patient with neuroblastoma
###end article-title 66
###begin article-title 67
Neurofibromatosis type 1 gene mutations in neuroblastoma
###end article-title 67
###begin article-title 68
RalGDS comes of age
###end article-title 68
###begin article-title 69
Species- and cell type-specific requirements for cellular transformation
###end article-title 69
###begin article-title 70
###xml 34 39 <span type="species:ncbi:9606">human</span>
Targeting the PI3K-Akt pathway in human cancer: rationale and promise
###end article-title 70
###begin article-title 71
Increasing complexity of the Ras signaling pathway
###end article-title 71
###begin article-title 72
###xml 30 35 <span type="species:ncbi:9606">human</span>
Mutations of the BRAF gene in human cancer
###end article-title 72
###begin article-title 73
###xml 50 55 <span type="species:ncbi:9606">human</span>
High frequency of mutations of the PIK3CA gene in human cancers
###end article-title 73
###begin article-title 74
Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins
###end article-title 74
###begin article-title 75
Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt
###end article-title 75
###begin article-title 76
###xml 52 67 <span type="species:ncbi:10090">transgenic mice</span>
Targeted expression of NMYC causes neuroblastoma in transgenic mice
###end article-title 76
###begin article-title 77
###xml 34 40 <span type="species:ncbi:10090">murine</span>
###xml 116 121 <span type="species:ncbi:9606">human</span>
Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors
###end article-title 77
###begin article-title 78
###xml 46 51 <span type="species:ncbi:10090">mouse</span>
Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma
###end article-title 78
###begin article-title 79
High-resolution detection and mapping of genomic DNA alterations in neuroblastoma
###end article-title 79
###begin article-title 80
Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma
###end article-title 80
###begin article-title 81
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas
###end article-title 81
###begin article-title 82
###xml 51 56 <span type="species:ncbi:9606">human</span>
Mutant PIK3CA promotes cell growth and invasion of human cancer cells
###end article-title 82
###begin article-title 83
Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer
###end article-title 83
###begin article-title 84
Mutations of PIK3CA in anaplastic oligodendrogliomas, high- grade astrocytomas, and medulloblastomas
###end article-title 84
###begin article-title 85
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations
###end article-title 85
###begin article-title 86
###xml 46 51 <span type="species:ncbi:9606">human</span>
###xml 125 130 <span type="species:ncbi:9606">human</span>
Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesis
###end article-title 86
###begin article-title 87
Identification and characterization of R-ras3: a novel member of the RAS gene family with a non-ubiquitous pattern of tissue distribution
###end article-title 87
###begin article-title 88
R-Ras promotes tumor growth of cervical epithelial cells
###end article-title 88
###begin article-title 89
PIK3CA as an oncogene in cervical cancer
###end article-title 89
###begin article-title 90
###xml 71 76 <span type="species:ncbi:9606">human</span>
Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma
###end article-title 90
###begin article-title 91
Mutation of the PIK3CA gene in ovarian and breast cancer
###end article-title 91
###begin article-title 92
###xml 124 129 <span type="species:ncbi:9606">human</span>
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
###end article-title 92
###begin title 93
Figures and Tables
###end title 93
###begin p 94
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 0 16 0 16 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>PIK3CA </italic>structure</bold>
PIK3CA structure. Schematic diagram of Pik3ca protein illustrating functional domains and mutations (grouped by domain) reported to date [22, 30, 32, 33, 40, 41]. Codons with frequent missense mutations reported ('hotspots') are denoted by asterisks. Location of experimentally found mutations in this study are denoted in boldface. p85, PI3K p85 regulatory subunit binding domain; RBD, Ras binding domain; C2, calcium-dependent phospholipid-binding domain; Helical, PI3K helical domain; Kinase, PI3/4-kinase domain.
###end p 94
###begin p 95
###xml 13 20 13 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 0 29 0 29 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Detection of <italic>PIK3CA </italic>mutations</bold>
Detection of PIK3CA mutations. Chromatogram tracing for exon 20 sequences encoding the catalytic kinase domain in primary neuroblastomas #1070 (A) and #1218 (B). Sequences demonstrate heterozygous alterations in these tumor samples as depicted by the arrows, with the amino acid change for #1070 being GAG (glutamic acid) to GAT (representing GAU, aspartic acid). Alterations were confirmed bi-directionally and in replicate sequencing. T, tumor DNA sequence; N, normal (or constitutional) DNA sequence. Note the tumor-specific (somatic) mutation in #1070, whereas the alteration in the 3'-UTR in #1218 is present in both tumor and constitutional DNA and likely represents a rare polymorphic variant.
###end p 95
###begin p 96
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 18 23 <span type="species:ncbi:9606">Human</span>
PIK3CA in Primary Human Neuroblastomas
###end p 96
###begin p 97
###xml 0 4 0 4 <bold xmlns:xlink="http://www.w3.org/1999/xlink">INSS</bold>
INSS; International Neuroblastoma Staging System.
###end p 97
###begin p 98
###xml 0 3 0 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">AMP</bold>
###xml 5 10 5 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
AMP; MYCN genomic amplification.
###end p 98
###begin p 99
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">S</bold>
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
S; single-copy MYCN per haploid genome.
###end p 99
###begin p 100
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink">wt</bold>
wt; wild-type sequence
###end p 100
###begin p 101
* Nucleotide position referenced from genomic sequence 1st nucleotide of exon 1.
###end p 101
###begin p 102
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
PIK3CA in Neuroblastoma cell lines
###end p 102
###begin p 103
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink">wt</bold>
wt; wild-type sequence.
###end p 103
###begin p 104
###xml 0 3 0 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">AMP</bold>
###xml 5 10 5 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
AMP; MYCN amplified.
###end p 104
###begin p 105
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">S</bold>
###xml 3 8 3 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
S; MYCN single-copy per haploid genome.
###end p 105
###begin p 106
* Position referenced from genomic sequence 1st nucleotide of exon 1.
###end p 106
###begin p 107
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras family</italic>
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Braf </italic>
###xml 21 28 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3CA </italic>
###xml 31 37 <span type="species:ncbi:10090">Murine</span>
Ras family, Braf and PIK3CA in Murine Neuroblastomas
###end p 107
###begin p 108
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink">wt</bold>
wt; wild-type sequence.
###end p 108
###begin p 109
* T denotes thoracic tumor (all others are retroperitoneal/abdominal).
###end p 109
###begin p 110
** MYCN transgene overexpressed in neural crest tissues.
###end p 110

